Regulating the immune response to tumours

Advanced Drug Delivery Reviews

Volumn 58, Issue 8, 2006, Pages 948-961

  Betts, Gareth J ^a   Clarke, Sarah L ^a   Richards, Hannah E ^a   Godkin, Andrew J ^a   Gallimore, Awen M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

T regulatory cells; Tumour immunity

Indexed keywords

ANTIGENS; CELLS; DISEASE CONTROL; PATIENT TREATMENT;

DISEASE PROGRESSION; T REGULATORY CELLS; TUMOUR IMMUNITY;

IMMUNOLOGY;

ANTIGEN; BASILIXIMAB; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL LYMPHOMA; TUMOR IMMUNITY; TUMOR REJECTION; VACCINATION;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 33750733260     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.05.006     Document Type: Review

References (80)

1. Pasare C., and Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr. Opin. Immunol. 15 (2003) 677-682
2. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560 (2005) 11-18
3. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
4. Kronenberg M., and Rudensky A. Regulation of immunity by self-reactive T cells. Nature 435 (2005) 598-604
5. Furtado G.C., de Lafaille M.A.C., Kutchukhidze N., and Lafaille J.J. Interleukin 2 signaling is required for CD4+ regulatory T cell function. J. Exp. Med. 196 (2002) 851-857
6. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., and Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
7. Wan Y.Y., and Flavell R.A. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5126-5131
8. Baecher-Allan C., Brown J.A., Freeman G.J., and Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol. 167 (2001) 1245-1253
9. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., and Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112 (2003) 1437-1443
10. Allan S.E., Passerini L., Bacchetta R., Crellin N., Dai M., Orban P.C., Ziegler S.F., Roncarolo M.G., and Levings M.K. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J. Clin. Invest. 115 (2005) 3276-3284
11. North R.J., and Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J. Exp. Med. 159 (1984) 1295-1311
12. Awwad M., and North R.J. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J. Exp. Med. 168 (1988) 2193-2206
13. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155 (1982) 1063-1074
14. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999) 5211-5218
15. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., and Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59 (1999) 3128-3133
16. Jones E., Dahm-Vicker M., Simon A.K., Green A., Powrie F., Cerundolo V., and Gallimore A. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol. 2 (2002) 1
17. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., and Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34 (2004) 336-344
18. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., and Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200 (2004) 771-782
19. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., and Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001) 823-832
20. Gray C.P., Arosio P., and Hersey P. Association of increased levels of heavy-chain ferritin with increased CD4+CD25+ regulatory T-Cell levels in patients with melanoma. Clin. Cancer Res. 9 (2003) 2551-2559
21. Wang X., Zheng J., Liu J., Yao J., He Y., Li X., Yu J., Yang J., Liu Z., and Huang S. Increased population of CD4+CD25 high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur. J. Haematol. 75 (2005) 468-476
22. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9 (2003) 606-612
23. + regulatory T cells in patients with gastrointestinal malignancies. Possible involvement of regulatory T cells in disease progression. Cancer 98 (2003) 1089-1099
24. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., Knolle P.A., Thomas R.K., von Bergwelt-Baildon M., Debey S., Hallek M., and Schultze J.L. Reduced frequencies and suppressive function of CD4+CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005) 2018-2025
25. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
26. Unitt E., Rushbrook M., Marshall R., Davies S., Gibbs P., Morris L., Coleman N., and Alexander G. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41 (2005) 722-730
27. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., and Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9 (2003) 4404-4408
28. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., Kaiser L.R., and June C.H. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168 (2002) 4272-4276
29. Liyanage U.K., Moore T.T., Joo H.-G., Tanaka Y., Herrmann V., Doherty G., Drebin J.A., Strasberg S.M., Eberlein T.J., Goedegebuure P.S., and Linehan D.C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169 (2002) 2756-2761
30. Kawaida H., Kono K., Takahashi A., Sugai H., Mimura K., Miyagawa N., Omata H., Ooi A., and Fujii H. Distribution of CD4(+)CD25 high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res. 124 (2005) 151-157
31. Yang Z.-Z., Novak A.J., Stenson M.J., Witzig T.E., and Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006) 3639-3646
32. Ziegler S.F. FOXP3: Of Mice and Men. Annu. Rev. Immunol. 24 (2006) 209-226
33. Viguier M., Lemaitre F., Verola O., Cho M.-S., Gorochov G., Dubertret L., Bachelez H., Kourilsky P., and Ferradini L. Foxp3 expressing CD4+CD25 high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173 (2004) 1444-1453
34. Badoual C., Hans S., Rodriguez J., Peyrard S., Klein C., Agueznay N.E.H., Mosseri V., Laccourreye O., Bruneval P., Fridman W.H., Brasnu D.F., and Tartour E. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12 (2006) 465-472
35. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.-T., Ohtani H., Old L.J., and Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18538-18543
36. Leong P.P., Mohammad R., Ibrahim N., Ithnin H., Abdullah M., Davis W.C., and Seow H.F. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol. Lett. 102 (2006) 229-236
37. Schaefer C., Kim G.G., Albers A., Hoermann K., Myers E.N., and Whiteside T.L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92 (2005) 913-920
38. Chen Y.-Q., Shi H.-Z., Qin X.-J., Mo W.-N., Liang X.-D., Huang Z.-X., Yang H.-B., and Wu C. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am. J. Respir. Crit. Care Med. 172 (2005) 1434-1439
39. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., and Vickers M.A. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 (2004) 1755-1762
40. Hiura T., Kagamu H., Miura S., Ishida A., Tanaka H., Tanaka J., Gejyo F., and Yoshizawa H. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J. Immunol. 175 (2005) 5058-5066
41. Fattorossi A., Battaglia A., Ferrandina G., Buzzonetti A., Legge F., Salutari V., and Scambia G. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol. Oncol. 92 (2004) 106-115
42. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., Deibl M., Gastl G., Gunsilius E., and Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 (2005) 8326-8331
43. Roncador G., Garcia J.F., Garcia J.F., Maestre L., Lucas E., Menarguez J., Ohshima K., Nakamura S., Banham A.H., and Piris M.A. FOXP3, a selective marker for a subset of adult T-cell leukaemia//lymphoma. Leukemia 19 (2005) 2247-2253
44. Alvaro T., Lejeune M., Salvado M.T., Bosch R., Garcia J.F., Jaen J., Banham A.H., Roncador G., Montalban C., and Piris M.A. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11 (2005) 1467-1473
45. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., Protschka M., Galle P.R., Neurath M.F., and Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol. 173 (2004) 6526-6531
46. Peng Y., Laouar Y., Li M.O., Green E.A., and Flavell R.A. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4572-4577
47. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., and Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202 (2005) 919-929
48. Nishikawa H., Jager E., Ritter G., Old L.J., and Gnjatic S. CD4+CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 106 (2005) 1008-1011
49. Nishikawa H., Qian F., Tsuji T., Ritter G., Old L.J., Gnjatic S., and Odunsi K. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J. Immunol. 176 (2006) 6340-6346
50. Maloy K.J., Salaun L., Cahill R., Dougan G., Saunders N.J., and Powrie F. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. 197 (2003) 111-119
51. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., Puig P.E., Novault S., Escudier B., Vivier E., Lecesne A., Robert C., Blay J.Y., Bernard J., Caillat-Zucman S., Freitas A., Tursz T., Wagner-Ballon O., Capron C., Vainchencker W., Martin F., and Zitvogel L. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202 (2005) 1075-1085
52. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., and Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176 (2006) 1582-1587
53. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., and Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65 (2005) 2457-2464
54. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., Shimizu J., and Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10 (1998) 1969-1980
55. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188 (1998) 287-296
56. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6 (2005) 338-344
57. Wang H.Y., Peng G., Guo Z., Shevach E.M., and Wang R.F. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 174 (2005) 2661-2670
58. Wang H.Y., Lee D.A., Peng G., Guo Z., Li Y., Kiniwa Y., Shevach E.M., and Wang R.F. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20 (2004) 107-118
59. Prasad S.J., Farrand K.J., Matthews S.A., Chang J.H., McHugh R.S., and Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol. 174 (2005) 90-98
60. Golgher D., Jones E., Powrie F., Elliott T., and Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32 (2002) 3267-3275
61. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., and Fu Y.X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201 (2005) 779-791
62. Needham D.J., Lee J.X., and Beilharz M.W. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem. Biophys. Res. Commun. 343 (2006) 684-691
63. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Menard C., Ghiringhelli F., Terme M., Carpentier A.F., Darrasse-Jese G., Lemonnier F., and Zitvogel L. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176 (2006) 2722-2729
64. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., Rosenberg S.A., and Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174 (2005) 2591-2601
65. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev., Cancer 3 (2003) 666-675
66. Foss F.M. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin. Lymphoma 1 Suppl. 1 (2000) S27-S31
67. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., and Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115 (2005) 3623-3633
68. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., and Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (denileukin diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28 (2005) 582-592
69. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
70. Ahmadzadeh M., and Rosenberg S.A. IL-2 administration increases CD4+CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
71. Nishikawa H., Kato T., Tawara I., Saito K., Ikeda H., Kuribayashi K., Allen P.M., Schreiber R.D., Sakaguchi S., Old L.J., and Shiku H. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J. Exp. Med. 201 (2005) 681-686
72. Nishikawa H., Kato T., Tanida K., Hiasa A., Tawara I., Ikeda H., Ikarashi Y., Wakasugi H., Kronenberg M., Nakayama T., Taniguchi M., Kuribayashi K., Old L.J., and Shiku H. CD4+CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10902-10906
73. Nishikawa H., Kato T., Tawara I., Takemitsu T., Saito K., Wang L., Ikarashi Y., Wakasugi H., Nakayama T., Taniguchi M., Kuribayashi K., Old L.J., and Shiku H. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9253-9257
74. Nishikawa H., Tanida K., Ikeda H., Sakakura M., Miyahara Y., Aota T., Mukai K., Watanabe M., Kuribayashi K., Old L.J., and Shiku H. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14571-14576
75. Wei W.Z., Jacob J.B., Zielinski J.F., Flynn J.C., Shim K.D., Alsharabi G., Giraldo A.A., and Kong Y.C. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+CD25+ regulatory T cell-depleted mice. Cancer Res. 65 (2005) 8471-8478
76. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., Duray P.H., Steinberg S.M., Allison J.P., Davis T.A., and Rosenberg S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8372-8377
77. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 (2004) 405-406
78. Erdman S.E., Poutahidis T., Tomczak M., Rogers A.B., Cormier K., Plank B., Horwitz B.H., and Fox J.G. CD4+CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162 (2003) 691-702
79. Erdman S.E., Sohn J.J., Rao V.P., Nambiar P.R., Ge Z., Fox J.G., and Schauer D.B. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+mice. Cancer Res. 65 (2005) 3998-4004
80. Sharma S., Yang S.C., Zhu L., Reckamp K., Gardner B., Baratelli F., Huang M., Batra R.K., and Dubinett S.M. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65 (2005) 5211-5220